2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-B0372A
    Bromhexine hydrochloride 611-75-6 99.93%
    Bromhexine hydrochloride is a potent and specific TMPRSS2 protease inhibitor with an IC50 of 0.75 μM. Bromhexine hydrochloride can prevent and manage SARS-CoV-2 infection. Bromhexine hydrochloride is an autophagy agonist. Bromhexine hydrochloride is a mucolytic cough suppressant and has the potential for a range of respiratory conditions.
    Bromhexine hydrochloride
  • HY-139142B
    Simufilam hydrochloride 2480226-07-9 99.85%
    Simufilam hydrochloride (PTI-125 hydrochloride) is an orally active FLNA modulator. Simufilam hydrochloride restores NMDAR signaling and Arc expression. Simufilam hydrochloride inhibits overactive mTOR signaling by restoring the normal conformation of FLNA, improves insulin sensitivity, reduces Aβ42-induced neuroinflammation and tau protein hyperphosphorylation. Simufilam hydrochloride can be used for research of Alzheimer's disease.
    Simufilam hydrochloride
  • HY-12699
    RO5166017 1048346-74-2 98.21%
    RO5166017 is an orally active and species-crosses TAAR1 agonist, with Ki values of 1.9 nM, 2.7 nM, 31 nM and 24 nM for mouse, rat, human and cynomolgus monkey, respectively.
    RO5166017
  • HY-16322
    Minodronic acid 180064-38-4 99.67%
    Minodronic acid (YM-529) is an FPP synthase inhibitor with an IC50 of 3 nM, and also an antagonist of P2X2/3 receptors with an IC50 of 62.7 μM. Minodronic acid induces tumor cell apoptosis and inhibits cell growth. Minodronic acid also suppresses bone resorption. Minodronic acid can be used in research related to osteoporosis and cancer.
    Minodronic acid
  • HY-19415
    SB-435495 304694-39-1 99.71%
    SB-435495 is a potent, selective, reversible, non-covalent and orally active Lp-PLA2 inhibitor with an IC50 of 0.06 nM.
    SB-435495
  • HY-27787
    α-Eleostearic acid 506-23-0 98.04%
    α-Eleostearic acid (cis-Eleostearic acid), a conjugated linolenic acid, is an apoptosis inducer. α-Eleostearic acid is also a ferroptosis inducer. α-Eleostearic acid exhibits antioxidant and antitumor activity.
    α-Eleostearic acid
  • HY-41982
    D-Glucuronic acid lactone 32449-92-6 ≥98.0%
    D-Glucuronic acid lactone (D-Glucurono-6,3-lactone; D-Glucurono-γ-lactone; D-Glucuronolactone; Dicurone; Glucoxy; Glucurolactone; Glucurone) is an endogenous metabolite and a glucuronic acid derivative. D-Glucuronic acid lactone serves as a starting reagent for the synthesis of 2,3,4-tris (tert-butyldimethylsilyl) glucuronic acid trichloroethyl ester, which is used to prepare 1-O-acyl glucuronic acids for the anti-inflammatory agent mL-3000 (HY-B1452), synthesize optically active glucuronic acids, and produce long-chain alkyl glucuronides. D-Glucuronic acid lactone shows potential for use in studies of reversible cerebral vasoconstriction syndrome (RCVS).
    D-Glucuronic acid lactone
  • HY-78000
    Methyl 4-formylbenzoate 1571-08-0 99.99%
    Methyl 4-formylbenzoate (4-Carbomethoxybenzaldehyde; 4-Carboxybenzaldehyde methyl ester; Terephthalaldehydic acid methyl ester; Methyl 4-formylbenzoate) is a intermediate that can be used for the synthesis of chalcone amide α-glucosidase inhibitors.
    Methyl 4-formylbenzoate
  • HY-B0730
    Pamidronate disodium pentahydrate 109552-15-0 98.0%
    Pamidronate disodium pentahydrate, the second-generation nitrogen-containing bisphosphonate, is an inhibitor of bone loss. Pamidronate disodium pentahydrate significantly inhibits subchondral bone loss in early osteoarthritis by upregulating the expression of osteoprotegerin in cartilage and subchondral bone, and inhibiting the expression of RANKL and MMP-9 in both tissues, as well as TLR-4 in cartilage, thereby alleviating cartilage degeneration. Additionally, Pamidronate disodium pentahydrate can inhibit the signaling of Wnt and β-catenin, and is applicable for research on osteoporosis and osteosarcoma.
    Pamidronate disodium pentahydrate
  • HY-B0840
    Chlorfenapyr 122453-73-0 99.39%
    Chlorfenapyr is a pyrrole insecticide. Chlorfenapyr has a mode of action: the mixed function oxidase oxidizes and removes the Nethoxymethyl group to form the active metabolite, CL 303268. Chlorfenapyr is used for termite control and crop protection against a variety of insect and mite pests.
    Chlorfenapyr
  • HY-I0637
    Isovanillin 621-59-0 ≥98.0%
    Isovanillin is an aldehyde oxidase inhibitor. Antispasmodic activities. Antidiarrheal activities.
    Isovanillin
  • HY-N0026
    2'-Acetylacteoside 94492-24-7 99.73%
    2'-Acetylacteoside (2'-AA) is a natural compound with oral activity and blood-brain barrier permeability. 2'-Acetylacteosideexhibits MAO‑B inhibitory activity (IC50 = 17.71 μM, Ki = 13.81 μM). 2'-Acetylacteoside downregulates the expression of RANK, TRAF6, NF‑κB, NFATc1 and IKKβ, disrupts the RANKL/RANK interaction, blocks downstream signaling pathways, and increases the level of phosphorylated Akt. 2'-Acetylacteoside possesses potent anti-osteoclastogenic, anti-bone resorptive, pro-neurogenic, neuroprotective and antioxidant activities. 2'-Acetylacteoside can be used in the research of osteoporosis, ischemic stroke and Parkinson's disease.
    2'-Acetylacteoside
  • HY-N0094
    Ipriflavone 35212-22-7 99.89%
    Ipriflavone is a synthetic isoflavone derivative used to suppress bone resorption.
    Ipriflavone
  • HY-N0374
    Licochalcone C 144506-14-9 99.55%
    Licochalcone C could inhibit α-glucosidase, with IC50s of <100 nM and 92.43 μM for α-glucosidase and protein tyrosine phosphatase 1B (PTP1B), respectively.
    Licochalcone C
  • HY-N0479
    Licarin B 51020-87-2 99.93%
    Licarin B, a nitric oxide production inhibitor extracted from the component of the seeds of Myristica fragrans, improves insulin sensitivity via PPARγ and activation of GLUT4 in the IRS-1/PI3K/AKT pathway.
    Licarin B
  • HY-N0909
    Notoginsenoside R2 80418-25-3 99.80%
    Notoginsenoside R2 (20(S)-Notoginsenoside R2; Ginsenoside Ng-R2) is an orally active notoginsenoside. Notoginsenoside R2 activates P90RSK and Nrf2 via the MEK1/2-ERK1/2 pathway to inhibit 6-OHDA-induced apoptotic damage in nerve cells. Notoginsenoside R2 upregulates SOX8/β-catenin by reducing miR-27a, thereby suppressing Aβ25-35-induced neuronal apoptosis and inflammatory responses. Notoginsenoside R2 alleviates lipid accumulation and mitochondrial dysfunction in diabetic nephropathy by inhibiting c-Src. Notoginsenoside R2 alleviates hepatic fibrosis by inducing hepatic stellate cell senescence and inhibiting the inflammatory microenvironment via JAK/STAT3 suppression. Notoginsenoside R2 can be used in research related to Parkinson's disease, Alzheimer's disease, diabetic nephropathy and hepatic fibrosis.
    Notoginsenoside R2
  • HY-N1426
    Raspberry ketone 5471-51-2 99.95%
    Raspberry ketone is a major aromatic compound of red raspberry, widely used as a fragrance in cosmetics and as a flavoring agent in foodstuff; also shows PPAR-α agonistic activity.
    Raspberry ketone
  • HY-N1468
    Agarotetrol 69809-22-9 99.88%
    Agarotetrol is a chromone derivative isolated from Agarwood.
    Agarotetrol
  • HY-N1504
    Loureirin B 119425-90-0 99.96%
    Loureirin B, a flavonoid extracted from Dracaena cochinchinensis, is an inhibitor of plasminogen activator inhibitor-1 (PAI-1), with an IC50 of 26.10 μM; Loureirin B also inhibits KATP, the phosphorylation of ERK and JNK, and has anti-diabetic activity.
    Loureirin B
  • HY-N2078
    Yamogenin 512-06-1 99.86%
    Yamogenin (Neodiosgenin) is a diastereomer of diosgenin. Yamogenin antagonizes the activation of the liver X receptor (LXR) in luciferase ligand assay. Yamogenin inhibits triacylglyceride (TG) accumulation through the suppression of gene expression of fatty acid synthesis in HepG2 hepatocytes. Yamogenin is a steroidal saponin that can be obtained from plant species with in vitro cytotoxicity, antioxidant, and antimicrobial properties. Yamogenin induces cell death via the extrinsic and intrinsic way of apoptosis. Yamogenin inhibits protein denaturation with an IC50 of 1421.92 μg/mL. Yamogenin can be studied in research on gastric cancer.
    Yamogenin
Cat. No. Product Name / Synonyms Application Reactivity